← All trials
NCT05382819
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 16, 2022
- Primary completion
- Oct 31, 2023
- Completion date
- Oct 31, 2023
- First posted
- May 19, 2022
- Last posted
- Sep 15, 2022
- Enrollment
- 129
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Fresh Tracks Therapeutics, Inc.Lead sponsor
- InnovadermCollaborator
- Syneos HealthCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.